Recombinant Mouse LIGHT/TNFSF14 Protein(Fc Tag) (PDMM100132)
Add to cart
For research use only.
| Synonyms | TNFSF, 1700013B14Rik, Light, Tnfsf14, TNFSF14, CD258, HVEML, LTg, TR2 |
| Species | Mouse |
| Expression Host | Mammalian |
| Sequence | Asp72-Val239 |
| Accession | Q9QYH9 |
| Calculated Molecular Weight | 43.37 kDa |
| Observed Molecular Weight | 50 kDa |
| Tag | C-Fc |
| Bio-activity | Not validated for activity |
| Form | Lyophilized powder |
| Purity | > 90% as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU/mg of the protein as determined by the LAL method |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
| Background | LIGHT , also known as TNFSF14 or CD258 , is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes , monocytes , granulocytes , spleen cells , and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM , which is predominantly expressed by T cells , and lymphotoxin β receptor (LTβR) , which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble non-signaling receptor , decoy receptor 3 (DcR3) , which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM , which is constitutively expressed in most lymphocyte subpopulations , including CD4+ and CD8+ T cells. In addition , TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus , TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment. |
| Cat.No. | Product Name | Clone No. |
|---|
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.sample_type}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
